Non-invasive urinary system urine tumor fluorescence developing reagent and use method thereof

Through non-invasive urinary urinary tumor fluorescence chromogenic reagents, combined with cell morphology and chemical fluorescence, the existing bladder cancer diagnosis methods are complicated to operate and easy to bleach, achieving high sensitivity and specific bladder cancer Cell recognition is suitable for large-scale screening, avoids interference from photobleaching and hematuria, and improves detection efficiency and accuracy.

CN119023640APending Publication Date: 2024-11-26HANGZHOU HUIDEKANG MEDICAL TECHNOLOGY CO LTD

Patent Information

Application Number
CN202411501608.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-25
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The existing bladder cancer diagnosis methods are complicated to operate, the detection rate is not high, and the fluorescent dye is easily photobleached, making it difficult to achieve non-invasive, convenient and accurate early and recurrence diagnosis.

Method used

Develop a non-invasive urinary urinary tumor fluorescent color development agent, which consists of fluorescein, stabilizers, antibleaching agents, anticoagulants and buffers, with a pH value of 4.0-8.0, and uses acridine orange as fluorescein to bind cells. Morphological and chemical fluorescence, cancer cells were determined by observing the fluorescence color of the cytoplasm and nucleus by fluorescence microscopy.

Benefits of technology

Achieve high sensitivity and specific large-scale screening, avoid photobleaching problems, quickly and accurately identify bladder cancer tumor cells, is suitable for various tissue shedding cells in the human body, eliminates hematuria interference, and improves detection efficiency and accuracy .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119023640A_ABST
    Figure CN119023640A_ABST
Patent Text Reader

Abstract

The invention discloses a non-invasive urinary system urine tumor fluorescence developing reagent and a use method thereof. The fluorescence developing reagent is composed of fluorescein, a stabilizer, an anti-bleaching agent, an anticoagulant and a buffer solution, the fluorescent color developing reagent comprises the following components in percentage by weight: 0.1%-2% of sodium chloride, 0.1%-5% of glycerol, 0.01%-1% of ethylenediamine tetraacetic acid or sodium salt or potassium salt thereof, 0.001%-0.01% of fluorescein, 1-10 mmol / L of an anti-bleaching agent and 0.01-1 mol / L of a buffer solution. After fluorescein staining, cell nucleuses show yellow green or yellow fluorescence, cytoplasm shows orange or flame fluorescence due to existence of more RNA, changes of cell morphology and chemical fluorescence can be observed at the same time according to the characteristic that cell morphology and chemical fluorescence are combined, and the defect that traditional Pasteur cytology staining is insufficient in sensitivity and specificity is overcome.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of analysis and detection, and in particular to a non-invasive urinary system urine tumor fluorescent colorimetric reagent for bladder cancer and a method for using the reagent. Background Art

[0002] Current clinical diagnostic methods for bladder cancer include imaging, cystoscopy and biopsy, fluorescence in situ hybridization (FISH), urine cytology, urine detection of bladder tumor markers (NMP22, BTA), and urine DNA methylation testing. The following briefly describes the advantages and disadvantages of these methods.

[0003] With the increasing popularity of fluorescence microscopy, acridine orange fluorescence (AO-F) has gained increasing attention for urine exfoliated cell staining. This method combines cell morphology with fluorescence chemistry, overcoming the shortcomings of the Papanicolaou (Papanicolaou) staining method in terms of sensitivity and accuracy. It produces rapid, clear cell images, making it easier to identify the presence of acridine orange. Regarding its detection principle, acridine orange binds simultaneously to both DNA and RNA in cells, producing distinct fluorescence colors. Its excitation peak is approximately 492 nm, and its fluorescence emission peaks are 530 nm (DNA) and 640 nm (RNA). It binds to double-stranded DNA by intercalation between the strands, while it accumulates on phosphate groups of single-stranded DNA and RNA through electrostatic attraction. This distinct binding mechanism results in distinct fluorescence colors. Under excitation with visible light at 488–502 nm, the cell nucleus fluoresces bright green (approximately 530 nm), while the nucleolus and cytoplasmic RNA fluoresce orange-red (~640 nm). Malignant tumor cells grow rapidly, and their nucleic acid metabolism, particularly DNA content, is higher than that of normal cells. Abnormally elevated nuclear DNA content can serve as an important marker for identifying tumor cells. Morphologically, tumor cells have scant cytoplasm that fluoresces orange-red or flame-red, large and malformed nuclei with mitotic activity, an imbalanced nuclear-to-cytoplasmic ratio, and yellow-green or yellow nuclei. Therefore, acridine orange staining, combining cell morphology with cell fluorescence chemical characterization, overcomes the limitations of Papanicolaou staining, which relies solely on cell morphology, and can be used as an auxiliary diagnostic method for bladder cancer. There are reports in the literature using acridine orange as a stain to identify tumor cells, but these methods are cumbersome and have low detection rates of approximately 70%. They also fail to address the issue of acridine orange's susceptibility to photobleaching. Therefore, the development of noninvasive, convenient, and accurate diagnostic methods to assist and improve bladder tumor detection reagents for timely and accurate diagnosis of early-stage and recurrent bladder cancer is of great scientific and clinical significance. Summary of the Invention

[0004] Based on the above analysis, the present invention discloses a non-invasive urinary system urine tumor fluorescence colorimetric reagent and a method of using the same.

[0005] The technical solution adopted by the present invention is: a non-invasive urinary system urine tumor fluorescence colorimetric reagent, the fluorescence colorimetric reagent components are composed of fluorescein, a stabilizer, an anti-bleaching agent, an anticoagulant and a buffer solution, and the pH value of the fluorescence colorimetric reagent is 4.0-8.0; The composition ratio of the fluorescent colorimetric reagent is as follows: sodium chloride 0.1%-2%, glycerol 0.1%-5%, ethylenediaminetetraacetic acid or its sodium salt or potassium salt 0.01%-1%, fluorescein content 0.001%-0.01%, anti-bleaching agent concentration 1-10 mmol / L, and buffer concentration 0.01-1 mol / L.

[0006] Preferably, the fluorescein is acridine orange.

[0007] Preferably, the buffer is one or more of Tris buffer, citrate buffer, citrate-phosphate buffer, acetic acid-acetate buffer or phosphate buffer.

[0008] The phosphate in the citrate-phosphate buffer is any one or more mixtures of disodium hydrogen phosphate, dipotassium hydrogen phosphate, sodium phosphate or potassium phosphate.

[0009] The acetate in the acetic acid-acetate buffer solution is either sodium acetate or ammonium acetate or a mixture of the two.

[0010] The phosphate buffer is any one of sodium dihydrogen phosphate-disodium hydrogen phosphate or potassium dihydrogen phosphate-dipotassium hydrogen phosphate or a mixture of the two.

[0011] Preferably, the stabilizer is glycerol-sodium chloride solution.

[0012] Preferably, the anti-bleaching agent is one or more of vitamin C, tris(2-carboxyethyl)phosphine, 6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid, cyclooctatetraene or glutathione.

[0013] Preferably, the anticoagulant is ethylenediaminetetraacetic acid or its sodium salt or potassium salt.

[0014] Another aspect of the present invention provides a method for using a non-invasive urinary system urine tumor fluorescence colorimetric reagent. The method comprises centrifuging 50-200 mL of the subject's urine, taking 10-15 µL of the cell residue at the bottom to smear on a glass slide, taking 15-18 µL of the non-invasive urinary system urine tumor fluorescence colorimetric reagent and dropping it on the glass slide for staining, adding a cover slide, and observing it under a fluorescence microscope. The test results are judged based on the following: under a microscope, the stained cytoplasm exhibits orange-red or flame-colored fluorescence; the nucleus exhibits yellow-green or yellow fluorescence, and is large and irregular, which is judged to be bladder cancer tumor cells; otherwise, it is normal.

[0015] This fluorescent colorimetric reagent has the following characteristics or advantages: 1. Accurate differentiation: It uses the combination of cell morphology and chemifluorescence to simultaneously observe changes in cell morphology and chemifluorescence, making up for the shortcomings of traditional Papanicolaou cytology staining in terms of sensitivity and specificity; 2. High detection: high sensitivity and specificity; 3. Eliminate interference: The main clinical symptom of urinary system tumors is hematuria. Hemoglobin has fluorescence inhibition, so this method is not affected by hematuria. 4. Not easy to be bleached: Acridine orange itself is easily bleached by light, which is not conducive to long-term observation of cell status and its clinical application is limited. The present invention overcomes this shortcoming; 5. Rapid determination: The Papanicolaou staining method or other staining methods using acridine orange in the literature have complex procedures and are not conducive to large-scale screening. The preparation method of the present invention is simple, rapid, and easy to operate, and is accurate and fast for non-invasive fluorescence colorimetry of urinary system tumors. 6. Wide application: Applicable to exfoliated cells from various tissues of the human body. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 This is a schematic diagram of fluorescence imaging used in the present invention to detect bladder cancer patients. DETAILED DESCRIPTION

[0018] In order to make the objects and advantages of the present invention more clearly understood, the present invention is further described below in conjunction with embodiments; it should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0019] The preferred embodiments of the present invention are described below with reference to the accompanying drawings. It should be understood by those skilled in the art that these embodiments are only used to explain the technical principles of the present invention and are not intended to limit the scope of protection of the present invention.

[0020] Example 1: Preparation of pH 6.0 phosphate-citrate buffer: Dissolve 8 g of sodium chloride, 8 mL of glycerol, 0.3 g of sodium ethylenediaminetetraacetic acid, and 0.25 g of Trolox in 992 mL of pure water. Use this solution to prepare 0.18 mol / L disodium hydrogen phosphate solution and 0.08 mol / L citric acid solution, respectively. Mix the two and adjust the pH to 6.0 with sodium hydroxide. Prepare acridine orange stock solution: Dissolve 1 g of acridine orange in 1 L of pure water to obtain a 1 mg / mL acridine orange stock solution. Prepare pH 6.0 fluorescent staining solution: dilute 40 mL of 1 mg / mL acridine orange stock solution in 920 mL of pH 6.0 phosphate-citrate buffer to obtain the fluorescent staining solution; then add 40 mL of a 1 mg / mL stabilizer glycerol-sodium chloride solution; add 20 mL of 2 mmol / L tris(2-carboxyethyl)phosphine; and then add 0.2 g of ethylenediaminetetraacetic acid; this is the noninvasive urinary system urine tumor fluorescence colorimetric reagent.

[0021] The reagent prepared in the above example is recorded as sample 1.

[0022] Example 2: To prepare a pH 7.0 phosphate buffer solution, dissolve 10 g of sodium chloride, 8 mL of glycerol, 0.3 g of sodium ethylenediaminetetraacetic acid, and 1 g of Trolox in 992 mL of pure water. Use this solution to prepare 0.1 mol / L disodium hydrogen phosphate solution and 0.1 mol / L sodium dihydrogen phosphate solution, respectively. Mix the two solutions and adjust the pH to 7.0 with potassium hydroxide. To prepare an acridine orange stock solution, dissolve 0.8 g of acridine orange in 1 L of pure water to obtain a 0.8 mg / mL acridine orange stock solution. Prepare pH 7.0 fluorescent staining solution: dilute 40 mL of 0.8 mg / mL acridine orange stock solution in 920 mL of pH 7.0 phosphate buffer to obtain the fluorescent staining solution. Then, add 40 mL of a 1 mg / mL stabilizer glycerol-sodium chloride solution; add 20 mL of a 2 mmol / L anti-bleaching agent vitamin C; and then add 0.1 g of ethylenediaminetetraacetic acid. This is the noninvasive urinary system urine tumor fluorescence colorimetric reagent.

[0023] The reagent prepared in the above example is recorded as sample 2.

[0024] Example 3: To prepare a pH 5.5 acetic acid-sodium acetate buffer solution, dissolve 8 g of sodium chloride, 10 mL of glycerol, 0.3 g of sodium ethylenediaminetetraacetate, and 1.76 g of vitamin C in 950 mL of pure water. This solution was used to prepare a 0.2 mol / L sodium acetate solution, and the pH was adjusted to 5.5 with glacial acetic acid. To prepare an acridine orange stock solution, dissolve 1 g of acridine orange in 1 L of pure water to obtain a 1 mg / mL acridine orange stock solution. To prepare a pH 5.5 fluorescent staining solution, take 20 mL of a 1 mg / mL acridine orange stock solution and dilute it in 990 mL of pH 5.5 acetic acid-sodium acetate buffer to obtain the fluorescent staining solution. Then, add 40 mL of a 1 mg / mL stabilizer glycerol-sodium chloride solution; add 20 mL of a 2 mmol / L 6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid; and then add 0.2 g of sodium ethylenediaminetetraacetic acid. This is the noninvasive urinary system urine tumor fluorescent colorimetric reagent.

[0025] The reagent prepared in the above example is recorded as sample 3.

[0026] Example 4: A pH 8.0 phosphate-citrate buffer solution was prepared by dissolving 8 g of sodium chloride, 8 mL of glycerol, 0.4 g of sodium ethylenediaminetetraacetic acid, and 2.86 g of tris(2-carboxyethyl)phosphine in 952 mL of pure water. This solution was used to prepare a 0.25 mol / L disodium hydrogen phosphate solution and a 0.15 mol / L citric acid buffer solution, respectively. The two solutions were mixed and the pH was adjusted to 8.0 with potassium hydroxide. An acridine orange stock solution was prepared by dissolving 1 g of acridine orange in 1 L of pure water to obtain a 1 mg / mL acridine orange stock solution. Prepare a pH 8.0 fluorescent staining solution by diluting 30 mL of a 1 mg / mL acridine orange stock solution in 970 mL of pH 8.0 phosphate-citrate buffer to obtain the fluorescent staining solution. Then, add 40 mL of a 1 mg / mL stabilizer glycerol-sodium chloride solution; add 20 mL of 2 mmol / L cyclooctatetraene or glutathione; and then add 0.5 g of potassium ethylenediaminetetraacetate to obtain a noninvasive urinary system urine tumor fluorescent colorimetric reagent.

[0027] The reagent prepared in the above example is recorded as sample 4.

[0028] Example 5: Prepare a pH 5.0 citric acid buffer solution by dissolving 8 g of sodium chloride, 20 mL of glycerol, 0.3 g of sodium ethylenediaminetetraacetic acid, and 8 mg of cyclooctatetraene in 940 mL of pure water. Use this solution to prepare a 0.1 mol / L citric acid solution, and then adjust the pH to 5.0 with potassium hydroxide. Prepare an acridine orange stock solution by dissolving 1 g of acridine orange in 1 L of pure water to obtain a 1 mg / mL acridine orange stock solution. Prepare a pH 5.0 fluorescent staining solution by diluting 60 mL of the 1 mg / mL acridine orange stock solution in 940 mL of pH 6.0 citric acid buffer to obtain a fluorescent staining solution. Then, add 40 mL of a 1 mg / mL glycerol-sodium chloride solution as a stabilizer; add 20 mL of 2 mmol / L tris(2-carboxyethyl)phosphine; and then add 0.6 g of sodium ethylenediaminetetraacetic acid to prepare a non-invasive urinary system urine tumor fluorescence colorimetric reagent.

[0029] The reagent prepared in the above example is recorded as sample 5.

[0030] Example 6: Preparation of pH 7.0 phosphate-citrate buffer: Dissolve 15 g of sodium chloride, 15 mL of glycerol, 0.5 g of sodium ethylenediaminetetraacetic acid, and 3.07 g of glutathione in 945 mL of pure water. Use this solution to prepare a 0.18 mol / L disodium hydrogen phosphate solution and a 0.1 mol / L citric acid solution, respectively. After mixing the two solutions, adjust the pH to 7.0 with potassium hydroxide. Prepare an acridine orange stock solution by dissolving 0.8 g of acridine orange in 1 L of pure water to obtain a 0.8 mg / mL acridine orange stock solution. Prepare a pH 7.0 fluorescent staining solution by diluting 60 mL of 0.8 mg / mL acridine orange stock solution in 940 mL of pH 7.0 phosphate-citrate buffer to obtain the fluorescent staining solution. Then, add 20 mL of a 1 mg / mL stabilizer glycerol-sodium chloride solution; add 20 mL of 2 mmol / L tris(2-carboxyethyl)phosphine; and then add 0.8 g of potassium ethylenediaminetetraacetate to obtain a noninvasive urinary system urine tumor fluorescent colorimetric reagent.

[0031] The reagent prepared in the above embodiment is sample 6.

[0032] In Example 7, 50 mL of urine from the subject was centrifuged, the supernatant discarded, and the sample resuspended in 100 µL of PBS. 10-15 µL of the cell residue at the bottom was taken and smeared on a glass slide. 15-18 µL of a non-invasive urinary system urine tumor fluorescence colorimetric reagent was dropped onto the slide for staining, which was then covered with a coverslip. The slide was then observed under a fluorescence microscope and the test results determined. Under the microscope, cells with orange-red or flame-colored cytoplasm fluorescence and yellow-green or yellow nuclei that were large and irregular were identified as bladder cancer cells; otherwise, they were normal.

[0033] The tumor marker staining results of samples 1-6 prepared in Examples 1-6 are shown in Table 1 below: Table 1

[0034] From Table 1, Figure 1 As can be seen, the non-invasive urinary system urine tumor fluorescent colorimetric reagent prepared by the present invention has a high percentage of tumor cell staining and accurate effect. Among them, the cell staining intensity of + indicates weak cell staining and incomplete cell staining; ++ indicates strong cell staining intensity and complete cell staining intensity; +++ indicates extremely strong cell staining and complete and clear cell staining.

[0035] Example 1 was applied to the test results of a hospital, where test samples 1-10 were normal people and test samples 11-20 were tumor patients. The results are shown in Table 2 below: Table 2 From Table 2, we can see that no tumor cells were detected in the 10 normal subjects. Except for the 17th patient sample, no tumor cells were detected in the other 10 patients. The detection rate of this sample is 90%. It is worth noting that Table 2 was used for testing in a certain hospital. Due to the influence of sample acquisition time and other factors, the actual detection effect is slightly lower than the laboratory detection effect in Table 1, but its 90% accuracy rate meets the existing detection needs. Among them, Indicates that no tumor cells were detected, and + indicates that tumor cells were detected.

[0036] Thus far, the technical solutions of the present invention have been described in conjunction with the preferred embodiments shown in the accompanying drawings. However, it will be readily understood by those skilled in the art that the scope of protection of the present invention is obviously not limited to these specific embodiments. Without departing from the principles of the present invention, those skilled in the art may make equivalent changes or substitutions to the relevant technical features, and the technical solutions after such changes or substitutions will fall within the scope of protection of the present invention.

Claims

1. A non-invasive urinary system urine tumor fluorescence colorimetric reagent, characterized in that: The fluorescent color developing reagent component is composed of fluorescein, a stabilizer, an anti-bleaching agent, an anticoagulant and a buffer solution, and the pH value of the fluorescent color developing reagent is 4.0-8.0; The composition ratio of the fluorescent colorimetric reagent is as follows: sodium chloride 0.1%-2%, propylene glycol 0.1%-5%, ethylenediaminetetraacetic acid or its sodium salt or potassium salt 0.01%-1%, fluorescein content 0.001%-0.01%, anti-bleaching agent concentration 1-10 mmol / L, and buffer concentration 0.01-1 mol / L.

2. A non-invasive urinary system urine tumor fluorescent colorimetric reagent according to claim 1, characterized in that: The fluorescein is acridine orange.

3. The non-invasive urinary system urine tumor fluorescence colorimetric reagent according to claim 1, characterized in that: The buffer is one or more of a tris buffer, a citrate buffer, a citrate-phosphate buffer, an acetic acid-acetate buffer or a phosphate buffer.

4. A non-invasive urinary system urine tumor fluorescence colorimetric reagent according to claim 3, characterized in that: The phosphate in the citrate-phosphate buffer is any one or more mixtures of disodium hydrogen phosphate, dipotassium hydrogen phosphate, sodium phosphate or potassium phosphate.

5. The non-invasive urinary system urine tumor fluorescence colorimetric reagent according to claim 3, characterized in that: The acetate in the acetic acid-acetate buffer is any one of sodium acetate and ammonium acetate or a mixture of the two.

6. The non-invasive urinary system urine tumor fluorescence colorimetric reagent according to claim 3, characterized in that: The phosphate buffer is any one of sodium dihydrogen phosphate-disodium hydrogen phosphate or potassium dihydrogen phosphate-dipotassium hydrogen phosphate or a mixture of the two.

7. The non-invasive urinary system urine tumor fluorescence colorimetric reagent according to claim 1, characterized in that: The stabilizer is glycerol-sodium chloride solution.

8. The non-invasive urinary system urine tumor fluorescence colorimetric reagent according to claim 1, characterized in that: The anti-bleaching agent is one or more of vitamin C, tris(2-carboxyethyl)phosphine, 6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid, cyclooctatetraene or glutathione.

9. The non-invasive urinary system urine tumor fluorescence colorimetric reagent according to claim 1, characterized in that: The anticoagulant is ethylenediaminetetraacetic acid or its sodium salt or potassium salt.

10. A method for using the non-invasive urinary system urine tumor fluorescent colorimetric reagent according to any one of claims 1 to 9, characterized in that: Centrifuge 50-200 mL of the subject's urine, take 10-15 µL of the cell residue at the bottom to smear on a glass slide, take 15-18 µL of non-invasive urinary system urine tumor fluorescent colorimetric reagent and drop it on the glass slide for staining and cover it with a glass slide, and observe it under a fluorescence microscope.

Citation Information

Patent Citations

  • Method of stabilizing dye solutions and stabilized dye compositions

    CA2563189A1

  • Method for detecting and classifying oncomelania hupensis blood lymphocyte by fluorescent staining liquor

    CN107607509A

  • Staining solution for cell staining and preparation method thereof

    CN113670696A

  • Reagent for quantitatively analyzing reticulocyte in human whole blood and application thereof

    CN116008045A

  • A natural non-toxic fluorescent protein dye from a non-bioluminescent marine invertebrate, compositions containing the said dye and its uses

    CN1649968A

Cited By

  • Immune chromogenic reagent for detecting malignant tumors in urine and application thereof

    CN121679025A

  • Immune color developing reagent for detecting malignant tumor in urine and application thereof

    CN121679025B